These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 11833591)
21. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline. Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396 [No Abstract] [Full Text] [Related]
22. Follow-on protein products: scientific issues, developments and challenges. Rathore AS Trends Biotechnol; 2009 Dec; 27(12):698-705. PubMed ID: 19846228 [TBL] [Abstract][Full Text] [Related]
23. Current regulatory issues in cell and tissue therapy. Burger SR Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234 [TBL] [Abstract][Full Text] [Related]
24. Exploring emerging nanobiotechnology drugs and medical devices. Paradise J; Diliberto GM; Tisdale AW; Kokkoli E Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467 [No Abstract] [Full Text] [Related]
25. The new FDA combination products programme. Donawa M Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330 [TBL] [Abstract][Full Text] [Related]
26. Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline. Dev Biol Stand; 1998; 93():223-34. PubMed ID: 9737399 [No Abstract] [Full Text] [Related]
27. Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Grilley BJ; Gee AP Cytotherapy; 2003; 5(3):197-207. PubMed ID: 12850787 [TBL] [Abstract][Full Text] [Related]
29. Quality of biotechnological products: stability testing of biotechnological/biological products. Annex to the ICH Harmonised Tripartite Guideline for the Stability Testing of New Drug Substances and Products. Dev Biol Stand; 1998; 93():211-9. PubMed ID: 9737398 [No Abstract] [Full Text] [Related]
30. Standards for medical devices in MRI: present and future. Woods TO J Magn Reson Imaging; 2007 Nov; 26(5):1186-9. PubMed ID: 17969160 [TBL] [Abstract][Full Text] [Related]
31. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline. Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397 [No Abstract] [Full Text] [Related]
32. Should human tissue transplants be regulated? Margolis RE Healthspan; 1992 Dec; 9(11):17-9. PubMed ID: 10123553 [No Abstract] [Full Text] [Related]
34. What are biologics? A comparative legislative, regulatory and scientific analysis. Korwek EL Food Drug Law J; 2007; 62(2):257-304. PubMed ID: 17632962 [No Abstract] [Full Text] [Related]
35. An FDA perspective of manufacturing changes for products in human use. Durfor CN; Scribner CL Ann N Y Acad Sci; 1992 Oct; 665():356-63. PubMed ID: 1416614 [No Abstract] [Full Text] [Related]
36. Development of probiotics as biologic drugs. Hoffman FA Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717 [TBL] [Abstract][Full Text] [Related]
37. Regulation of biologicals in the European Union. Vicari G Dev Biol Stand; 1999; 100():145-8. PubMed ID: 10616185 [No Abstract] [Full Text] [Related]
38. Definition of a well-characterized biotechnology product. Zoon K; Garnick R Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531 [No Abstract] [Full Text] [Related]
39. SuperGenerics: a better alternative for biogenerics. Charles SA Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591 [No Abstract] [Full Text] [Related]
40. Current status of regulating biotechnology-derived animals in Canada: animal health and food safety considerations. Kochhar HP; Evans BR Theriogenology; 2007 Jan; 67(1):188-97. PubMed ID: 17097725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]